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Objective: To evaluate the efﬁcacy of some medicinal plants and systemic glucantime in
a comparative manner against the causative agent of cutaneous leishmaniasis both in vitro
and in BALB/c mice.
Methods: For in vivo testing, inbred mice were challenged with Leishmania major
parasites and the resultant ulcers were treated with extract based-ointments applied
topically two times per day for a period of 20 days. A group of 56 mice were randomly
divided into 7 subgroups. The control group received the ointment void of extracts,
whereas the reference group received glucantime only. The efﬁcacy of treatments was
evaluated by measuring ulcer diameter, parasite burden and NO production.
Results: Our results indicated that plant extract based-ointments were effective in
reducing ulcer size and parasite burden in spleens, but their effects did not differ
signiﬁcantly from that of glucantime. The plant extracts tested in this study were able to
increase NO production that helped parasite suppression.
Conclusions: Our ﬁndings indicate that the tested plant extracts are effective against
Leishmania major both during in vitro and in vivo experiments, but further researches are
required to recommend a potential plant extract as an alternative drug.1. Introduction
As a vector-borne parasitic disease, leishmaniasis has a
spectrum of clinical manifestations from self-healing skin ulcers,
mucosal damages to serious visceral infections [1]. According to
the World Health Organization, leishmaniasis is one of the most
neglected re-emerging and uncontrolled tropical diseases. TheHIV and Leishmania coinfection is quickly growing in number
in countries where Leishmania species are endemic. The disease
is reported from many parts of the world with an estimated
prevalence of about 12 million cases. However, the incidence of
cutaneous leishmaniasis (CL) and visceral leishmaniasis is
estimated to be about 1.5–2 million and 500000 new cases each
year, respectively [2,3]. Upon inoculation in the dermis, the
leishmanial promastigotes are phagocytosed by macrophages
before interacting with extracellular matrix components to
produce variable clinical syndromes [4]. In developing
countries, the medicinal plants have long been used for
disease treatment because they are safe and available at low
price. Given the various beneﬁcial drugs derived from
medicinal plants, discovering new sources of drugs against
Leishmania infection would be of high signiﬁcance [5–7]. This
research was undertaken in order to respond to aggravating
situation of leishmaniasis in Iran, manifested in high
prevalence, drug resistance, costly and lengthy treatment andarticle under the CC BY-NC-ND license (http://
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line therapies [8,9]. In this study, we examined the efﬁcacy of a
number of plant extracts against Leishmania major (L. major)
parasite both in vivo using infected BALB/c mice and in vitro
using parasite cultures. The plant extracts were derived from
Carthamus tinctorius (Family: Asteraceae) (C. tinctorius) or
safﬂower, Pimpinella anisum (Family: Apiaceae) (P. anisum),
Cuminum cyminum (Family: Apiaceae) (C. cyminum),
Cinnamomum verum (Family: Lauraceae) (C. verum) and
Alhagi persarum (Family: Fabaceae) (A. persarum) [10–15].
Due to its diversity of climate, Iran is home for
aforementioned plants where they grow profusely. The plants
have already shown many therapeutic effects against
helminths, bacteria, fungi and viruses. Also, the plants are
used in traditional medicine as health maintaining supplements
and useful drugs against diarrhea in children [16,17]. It is worth
noting that the World Health Organization has accorded high
priority and signiﬁcance to investigation of medicinal plants as
traditional drugs for leishmaniasis treatment [18,19].
2. Materials and methods
2.1. Medicinal plants preparation
Seeds of C. tinctorius, P. anisum, C. cyminum, juice and stem
of C. verum and bark of A. persarum which were endemic to
Iran, were obtained from Research Institute for Islamic and
Complementary Medicine in Iran (Tehran), in July 2014, during
their ﬂowering stages. The plants were taxonomically veriﬁed by
botanists from the herbarium of the above-mentioned institute in
Tehran, Iran and preserved under voucher specimens No. 2338,
1135, 1172, 528 and 2110, respectively.
These green plants are cultivated in different parts of
Iran such as Lordegan Region in Chaharmahal and Bakhtiari
Province as well as in Kerman, Shiraz, Ardabil Provinces.
The crude extracts were obtained by maceration of 100 g of
plants to which 100 mL methanol was added in a dark place at
room temperature. After 7 days, the pure extracts were ﬁltered
and the solvents were removed using a rotary evaporator. The
dried extracts were kept in dark amber colored containers. All
concentrations of the extracts were made on the basis of dry
weight of extract per volume.
2.2. Anti-leishmanial drug
There are two common therapies containing antimony
(known as pentavalent antimonial), meglumine antimoniate
(glucantime) and sodium stibogluconate (Pentostam). We used
meglumine antimoniate purchased from Sigma (Sigma Chemical
Co., St Louis, MO). Glucantime was injected intramuscularly at
20 mg/kg/day for 20 days.
2.3. Parasite culture
The standard strain of L. major (MRHO/IR/75/ER) was
obtained from the School of Public Health (Tehran University
of Medical Sciences, Iran). The parasite was cultured in Novy-
MacNeal-Nicolle medium before being mass produced in
RPMI-1640 containing 10% fetal bovine serum, 292 mg/mL L-
glutamine and 4.5 mg/mL glucose as well as 100 IU/mL
penicillin and 100 mg/mL streptomycin for bacterialdecontamination (all chemicals obtained from Sigma). The
cultures were incubated at 25 C and the stationary phase of
parasite growth was obtained after 6 days and used within 14
days post-incubation [20].
2.4. Concentrations of plant extracts
The plant extracts and anti-leishmanial drug were dissolved
in phosphate-buffered saline and prepared for biological testing
at the following concentrations: 0.05, 0.1, 0.2 and 0.4 mg/mL. To
test the anti-leishmanial activity of concentrated plant extracts,
solutions were prepared by dissolving the powdered extracts in
20% dimethyl sulfoxide (DMSO) followed by 5 min of soni-
cation to make a stock solution of 100 mg/mL. The solutions
were then stored at −20 C before being ﬁltered through 0.2 mm
ﬁlter at the time of application. The concentration of DMSO in
the solutions was kept at  1%.
2.5. In vitro experiments
The anti-leishmanial activities of plant extracts were tested
on late log phase of L. major promastigotes inoculated in RPMI
medium supplemented with 10% fetal calf serum at 106 para-
sites/mL. The viability of parasites was assayed in duplicate
against ascending concentrations of plant extracts. The viable
promastigotes were then counted after 24 h incubation period at
25 C using a Neubauer chamber. The IC50 of the extracts was
calculated as a concentration capable of inhibiting 50% of
parasite growth. A negative and a positive control were added to
each set of experiment using phosphate-buffered saline and
glucantime as growth inhibitors, respectively. The protocol of
in vivo experiments was approved by the Institutional Ethics
Committee.
2.6. Experimental animals
BALB/c inbred females, aged 4–5 weeks and weighed 30–
40 g were obtained from Razi Vaccine and Serum Research
Institute (Karaj, Iran) and kept in standard boxes under
controlled light and temperature conditions. Fifty-six BALB/c
female mice, randomly divided into seven groups, were used for
experimentation. Both experimental and control mice were fol-
lowed up for 1 more month at the end of treatment periods. The
approval for procedures using experimental animals was sought
from Ethics Committee of Research of Iran University of
Medical Sciences (Tehran, Iran).
2.7. Preparation of extract based-ointments
The extract based-ointments were prepared as per the
following formulation: dried plant extract (20%) was added to
lanolin (10%) and DMSO (12%) before being integrated in soft
parafﬁn. The white soft parafﬁn served as a greasy ointment base
to incorporate the abovementioned materials. Lanolin was added
to enhance the hydrophilicity of the preparations. DMSO was
also used as penetration enhancer and was used to improve the
drug absorption through the skin. To economize, the extract
concentrations for in vivo experiments were prepared based on
their best results during in vitro experiments. No preservative
was added and the ointments were kept at 4 C and used within
7 days after preparation.
Fatemeh Maleki et al./Asian Pac J Trop Biomed 2017; 7(1): 37–42 392.8. In vivo experiments
To initiate Leishmania infection, an inoculum of at least
106 stationary phase promastigotes was intradermally injected
in the tail base of each mouse. The mice were then distributed
into the following groups: the test group which received glu-
cantime (gold standard) and plant extracts and the control
group which received the ointment void of plant extracts. The
inoculated mice developed nodules and ulcers after 30 days.
Upon developing ulcers, the infected mice were treated by
applying the preparations twice daily at the ulcer site (early
morning and late afternoon) over a 20-day period. To ﬁx the
applied dose, 200 mg of each ointment was weighed and
applied per mouse per day using a cotton applicator. Glu-
cantime was injected intramuscularly at 20 mg/kg/day. A Kulis
Vernier was used to measure lesions diameters of the treated
mice which were then weighed by a digital scale at weekly
intervals. At the end of the treatment, the mice were followed
up for 1 month.
2.9. Parasite burden determination
To determine the parasite burden, 3 mice from each group
were sacriﬁced after 4 weeks of treatment to obtain spleen
samples. The spleen samples were aseptically weighed and ho-
mogenized in 2 mL of Schneider's Drosophila medium con-
taining 20% heat-inactivated fetal calf serum and 0.1%
gentamicin. The homogenates were subjected to serial dilutions
ranging from 1 to 1/4 × 10−4 in 96-well tissue culture plates
under sterile conditions. The plates were incubated at 26 C and
examined for mobile promastigotes at 7 and 15-day post-
incubation using an inverted microscope at 40× magniﬁcation.
The dilution was made so that the last titer (well) contained at
least one parasite. The parasite burden (cell/g tissue) was
quantiﬁed as per following equation [21]:
Parasite burden = −log10 (Parasite dilution/Tissue weight)
2.10. Determination of NO
Griess reaction assay was employed for nitrite levels deter-
mination. To this end, peritoneal macrophages were harvested
from both untreated mice and those exposed to various doses of
plant extracts or glucantime. The harvested macrophages were
cultured in ﬂask before the adherent cells were removed by
gentle scraping and washed with warm medium (25 C). The
macrophages were then counted and their viability was deter-
mined. The viable cells were further cultured in 24-well plates
before incubation in 5% CO2 at 37 C for 18 h. After the
removal of non-adherent cells, the plant extracts were added to
wells either with or without 0.2 mmol/L L-NG-monomethyl
arginine as NO synthase inhibitor. The supernatants were
collected after 48 h and nitrite accumulation was assayed using
Griess reagent [22].
2.11. Statistical analysis
Two-way ANOVA and student's t-test were used to
analyze mean values. The experimental data were summarizedusing mean ± SEM. The statistical signiﬁcant level for dif-
ferences between mean values was accepted at P < 0.05.
SPSS software version 12 was employed for statistical
analyses.
3. Results
The plant extracts and glucantime inhibited 50% of the
promastigote growth in vitro after 72 h (IC50). The results
depicted the in vitro inhibitory effect of plant extracts and
the drug against L. major promastigotes. In vitro effects of
the plant extracts on L. major promastigotes showed that
death parasites in P. anisum, C. verum, C. tinctorius,
C. cyminum, and A. persarum extracts were 80.08%, 74.16%,
70.14%, 60.75% and 36.58%, respectively. The plant extracts
yielded the best results at 0.4 mg/mL concentration during
in vivo experimentations. P. anisum, C. verum, C. tinctorius,
C. cyminum, and A. persarum extracts and glucantime had an
IC50 of (15.00 ± 0.65), (17.00 ± 0.91), (23.00 ± 0.59),
(31.00 ± 0.71), (45.00 ± 0.61) and (20.00 ± 0.82) mg/mL,
respectively.
Upon injection of the parasite into the mice tail bases, nod-
ules developed 3–4 weeks later. The nodules then changed into
ulcers after 1–2 weeks and increased in size. Anti-leishmanial
activity of plant extracts was evaluated by measuring the
lesion sizes and mice weights.
Our results showed that the plant extracts had no signiﬁ-
cant positive effect on the mice weights in the ﬁrst week.
However, slight weight losses occurred in the following
weeks until the fourth week. In the control group, however,
weight losses were considerable. The weight losses of mice
in the test groups were not signiﬁcantly different from those
in glucantime treated group but differed from the control
group.
The ulcer sizes in the test groups (treated with extracts)
were signiﬁcantly smaller than those in the control group, but
they were not signiﬁcantly different from glucantime treated
group. The diameters of ulcers treated with C. cyminum and
P. anisum extracts were almost similar to those treated with
glucantime. Also, A. persarum, C. verum and C. tinctorius
extracts caused reduction of the ulcers diameters in treated
mice compared with control group which exhibited ulcers of
signiﬁcantly growing sizes. However, none of treatments
could result in complete healing of the lesions as shown in
Tables 1 and 2 (P  0.05).
The parasite counts in the spleen cells showed signiﬁcant
reduction in the test group in comparison with the control group.
The mean number of parasites (per mg of spleen tissue) in
C. cyminum, P. anisum, C. verum, C. tinctorius, A. persarum,
glucantime and control was 4.9 ± 1.1, 4.2 ± 1.9, 4.4 ± 2.3,
4.7 ± 3.2, 5.8 ± 1.8, 3.9 ± 2.8 and 7.0 ± 3.1, respectively.
However, no signiﬁcant difference was observed between
extract- and glucantime-treated groups in terms of parasite
counts.
On the other hand, extracts based-ointments and glucantime
have induced statistically similar level of NO production,
though P. anisum resulted in the highest amount of NO
amongst all treatments. Our results showed that the plant ex-
tracts used in this research can promote NO production by
murine macrophages. NO production was induced by plant
Table 2
Lesion sizes (mm) in each test group compared with those in control and glucantime-treated groups.
Time C. cyminum P. anisum C. verum C. tinctorius A. persarum Glucantime Control
Week 0 1.30 ± 0.23 1.10 ± 0.20 1.20 ± 0.65 1.20 ± 0.49 1.20 ± 0.29 1.30 ± 0.68 1.10 ± 0.49
Week 2 1.30 ± 0.30 1.10 ± 0.10 1.20 ± 0.22 1.20 ± 0.59 1.30 ± 0.54 1.30 ± 0.33 1.80 ± 0.50
Week 3 1.50 ± 0.32 1.40 ± 0.48 1.40 ± 0.39 1.50 ± 0.42 1.80 ± 0.61 1.60 ± 0.53 2.00 ± 0.52
Week 4 1.60 ± 0.40 1.50 ± 0.71 1.70 ± 0.55 1.90 ± 0.11 2.00 ± 0.67 1.70 ± 0.58 2.30 ± 0.25
Values are expressed as mean ± SD.
Table 1
The mice weights (g) in each test group compared with those in control and glucantime-treated groups.
Time C. cyminum P. anisum C. verum C. tinctorius A. persarum Glucantime Control
Week 0 21.00 ± 1.16 21.40 ± 1.45 20.80 ± 0.89 21.80 ± 0.92 21.00 ± 0.78 21.40 ± 0.83 21.50 ± 1.00
Week 2 21.00 ± 1.51 21.50 ± 1.50 20.00 ± 0.95 21.70 ± 0.77 20.00 ± 0.86 21.47 ± 0.79 20.00 ± 1.10
Week 3 21.10 ± 0.91 21.60 ± 1.20 19.00 ± 0.99 21.60 ± 0.80 20.00 ± 0.90 21.59 ± 0.91 18.50 ± 1.30
Week 4 21.00 ± 0.87 21.70 ± 1.13 18.20 ± 0.97 20.80 ± 0.88 19.10 ± 1.13 21.80 ± 1.20 15.00 ± 1.12
Values are expressed as mean ± SD.
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C. tinctorius: 9.9 mm/mL, C. cyminum: 9.1 mm/mL and
A. persarum: 8.4 mm/mL) and glucantime (10.5 mm/mL)
compared with control group (6.1 mm/mL).
4. Discussion
Amongst leishmaniasis forms, CL is the most commonly
encountered one. Iran and its neighboring countries,
Afghanistan, Pakistan, Iraq and Saudi Arabia, accommodate
almost 90% of CL cases [23]. A number of chemical, physical
and surgical therapies have been recommended for the
treatment of CL. However, drug resistance by parasite to
chemotherapeutic agents remains a serious obstacle in the way
of treating leishmaniasis. Pentavalent antimonial therapy
constitutes the ﬁrst-line treatment for CL worldwide since
1945 [24,25]. In a bid to escape disadvantages of
chemotherapeutic agents including drug resistance, this study
has been conducted to evaluate the in vitro and in vivo effects
of plant extracts obtained from C. tinctorius, P. anisum,
C. cyminum, C. verum and A. persarum on L. major in
comparison with glucantime. The necessity of the study was
emphasized by the growing interest in natural products
including medicinal plants as alternative therapies for CL.
Several studies have already tackled the screening of plant
extracts against leishmaniasis. This study, however, clearly
indicated high efﬁcacy of some medicinal herbs in inhibiting
promastigotes growth during in vitro and in vivo
experimentations. The medicinal plants examined in this
research have a long history of use in Chinese medicine.
Being common table vegetable available all over Iran, these
plants have antiviral and anti-parasitic effects [26–28]. Given
the lack of data about the natural ingredients of these plants
and their effects against leishmaniasis, this study aimed to
investigate their therapeutic effects on leishmanial lesions
inﬂicted on BALB/c mice compared with glucantime effects.
Our results showed that the plant extracts produced signiﬁ-
cant decrease in parasite burden and lesion size in all treated
mice groups compared with the control group (P  0.05).
Various Artemisia concentrations (1%, 3% and 5%) failed to
reduce diameters of CL lesions after 30 days of treatment
compared with control group, whereas extracts of Thymusvulgaris, Achillea millefolium and propolis were more effective
in reducing ulcer than glucantime [29,30]. Bafghi et al. found that
the mean lesion sizes of mice receiving Rubia tinctorum extracts
at 40%, 60% and 80% concentrations were not signiﬁcantly
different from those in control group (P > 0.05) [31]. The
abovementioned studies are in agreement with our results.
However, Akhlaghi et al. examined the effect of Hyssopus
ofﬁcinalis, Tussilago farfara, Carum copticum extracts on
mice infected with L. major and showed that plants ointments
were effective in reducing ulcer size and burden parasite in
spleen [21]. Fata et al. have stated that, upon 2 weeks
application, the ethanolic extract of Berberis vulgaris
considerably decreases the lesion size caused by L. major in
BALB/c mice [32]. Hejazi et al. showed signiﬁcant difference
between mean of lesion sizes among treated and untreated
mice using yarrow (Bomadaran) and thyme (Avishan) extracts,
although the plant extracts were as effective as glucantime [33].
Rahimi-Moghaddam et al. examined the in vitro effect of
Peganum harmala against L. major and found a concentration-
dependent decrease of parasite count, recording an IC50 value of
59.4 mg/mL. Conducting in vivo studies, they, also, demon-
strated a signiﬁcant post-treatment decrease in the lesion size
and parasite count in infected animals, compared to placebo and
control groups [20]. The abovementioned ﬁndings support our
results. We showed that despite the fact that P. anisum extract
produces comparable weight loss in mice, it is more effective
than other extracts in reducing ulcer diameters and enhancing
NO production. In fact, P. anisum extract produced almost
similar anti-leishmanial activities as glucantime (P < 0.05).
Therefore, P. anisum extract may be recommended as an
appropriate drug for treating CL. The lowest parasite load in the
spleen was observed in mice treated with P. anisum followed by
those treated with C. verum, C. tinctorius, C. cyminum and
A. persarum in a descending order of efﬁcacy. We, also,
observed that within test groups treated with P. anisum and
C. cyminum extracts, 2 out of 8 mice had their lesions
completely healed. Despite the notion that, in L. major infected
BALB/c mice, the NO production decreases naturally due to
amastigote actions, our results indicated that the plant extracts
may restore NO production as a mechanism of parasite elimi-
nation. Some authors have already shown that artemisinin can
cause 50% reduction in parasite burden of macrophages infected
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the contrary of the effect of Scrophularia striata ethanolic
extract which suppressed the ability of murine peritoneal
macrophages to produce NO during in vitro and ex vivo
experiments [35]. On the other hand, using RT-PCR technique,
Gharavi et al. found that garlic extract promotes interferon
gamma and inducible nitric oxide synthase genes expression in
L. major infected J774 cells which can serve as an indication for
more NO production [36]. However, the pathways underlying
this kind of mechanism by plant extracts remain to be deeply
understood.
It has been shown that NO production is part of micro-
bicidal activity of macrophages to eliminate infectious intra-
cellular pathogens such as L. major, Toxoplasma gondii and
Trypanosoma cruzi. NO acts as an anti-leishmanial agent in
mice macrophages by reducing parasite number within lesions.
It seems that the development of intracellular amastigotes may
be inhibited by both endogenous and exogenous NO. This
ﬁnding is conﬁrmed by in vitro and in vivo immunological
studies in which NO radical within leishmanial lesions was
responsible for parasite count reduction. The decrease in
parasite burden can be due to stimulation of natural killer cells
activator release by macrophages of both nitric acid and tumor
necrosis factor [37,38].
Our study revealed that the tested plant extracts have a
promising chemotherapeutic activity against L. major with
P. anisum extract being of the potential to be recommended as a
candidate for leishmaniasis treatment. In general, medicinal
plants can offer promising drugs against CL. However, based on
our data, further researches are required to elucidate the thera-
peutic mechanism of plant extracts against L. major both in
animal models and human if we want to recommend a plant
extract as a drug.
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